The Daytrana patch is a prescription central nervous system (brain) stimulant medicine used to treat ADHD in children 6 to 17 years old.

Daytrana will be marketed and sold by Noven Therapeutics, Noven’s specialty pharmaceuticals marketing and sales unit.

Noven Pharma president and CEO Jeffrey Eisenberg said that they are very pleased to complete the acquisition and to add Daytrana – a product developed and manufactured by Noven – to the portfolio of products that they market and sell through Noven Therapeutics.

“Daytrana continues to represent an important therapeutic option in the treatment of ADHD. As an organisation, we’re excited to begin active promotion of the product, with the goal of increasing awareness of Daytrana and helping patients, physicians and caregivers manage the symptoms of ADHD,” Eisenberg said.